Figure 1

Coronary Artery Disease Evaluation in Rheumatoid Arthritis (CADERA) study flow diagram. *Etanercept non-responders or intolerance managed at physician’s discretion. ^#Methotrexate for duration of study, addition of other DMARDs at week eight if not in remission and escalated to etanercept at week 24 if not in remission. ^~Etanercept discontinued at the primary endpoint unless clinically indicated and at physician’s discretion. DAS, disease activity score; DMARD, disease modifying anti-rheumatic drug; HRUS, high-resolution ultrasound; LTHT, Leeds Teaching Hospitals NHS Trust; MCP, metacarpophalangeal; RA, rheumatoid arthritis; TT, treat-to-target; VEDERA, Very Early versus Delayed Etanercept in Rheumatoid Arthritis.